Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

PZ0383

Sigma-Aldrich

Palbociclib

≥98% (HPLC), powder, CDK 4 & 6 inhibitor

Synonyme(s) :

6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one, Ibrance, PD 0332991, PD 332991, PD-0332991, PD0332991, PD991, PF 00080665, PF-00080665, PF00080665

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C24H29N7O2
Numéro CAS:
571190-30-2
Poids moléculaire :
447.53
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Nom du produit

Palbociclib, ≥98% (HPLC)

Essai

≥98% (HPLC)

Forme

powder

Couleur

white to beige

Solubilité

0.1 M HCl: 2 mg/mL, clear

Température de stockage

room temp

Chaîne SMILES 

CC(C1=C(N2C3CCCC3)N=C(NC4=CC=C(N5CCNCC5)C=N4)N=C1)=C(C(C)=O)C2=O

InChI

1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)

Clé InChI

AHJRHEGDXFFMBM-UHFFFAOYSA-N

Actions biochimiques/physiologiques

PF-00080665 (Palbociclib; PD 0332991) is an orally active and highly specific inhibitor against cyclin-dependent kinase 4 & 6 (IC50 = 9, 11, 15 nM, respectively, using CDK4/cycD3, CDK4/cycD1, CDK6/cycD2; IC50 >10 μM against 36 other kinases) that potently suppresses Cdk4/6-dependent cellular Rb phosphorylation (IC50 = 66 nM/pSer780 & 63 nM/pSer795; MDA-MB-435). PF-00080665 exhibits selective antiproliferation activity against Rb-positive human breast/colon/lung/leukemia cancer cultures (IC50 = 40-400 nM; IC50 >3 μM/Rb-negative MDA-MB-468 & H2009) and displays in vivo efficacy against various advanced stage human tumor xenografts in mice (12.5-150 mg/kg/day p.o.).

Stockage et stabilité

This chemical can be stored in solution at -80°C for 6 months and at -20°C for 1 month (protect from light).

Pictogrammes

Health hazardEnvironment
GHS08,GHS09

Mention d'avertissement

Warning

Mentions de danger

H341,H361f,H373,H411

Classification des risques

Aquatic Chronic 2 - Muta. 2 - Repr. 2 - STOT RE 2 Oral

Organes cibles

Bone marrow,male reproductive organs

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Flavopiridol hydrochloride ≥98% (HPLC), powder

Sigma-Aldrich

F3055

Flavopiridol hydrochloride

Pazopanib

Sigma-Aldrich

CDS023580

Pazopanib

Roscovitine ≥98% (TLC)

Sigma-Aldrich

R7772

Roscovitine

Nilotinib

Sigma-Aldrich

CDS023093

Nilotinib

Dasatinib ≥98% (HPLC)

Sigma-Aldrich

SML2589

Dasatinib

Fulvestrant European Pharmacopoeia (EP) Reference Standard

Y0001413

Fulvestrant

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
Daniele Cretella et al.
Journal of experimental & clinical cancer research : CR, 37(1), 72-72 (2018-03-29)
E Martínez de Dueñas et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018-03-23)
Cyclin-dependent kinases (CDKs) play a key role in cell cycle regulation, which makes them a clear therapeutic target to interfere with cell division and proliferation in cancer patients. Palbociclib, a specific inhibitor of CDK4/6 with outstanding clinical efficacy data and
Shinya Kitamura et al.
Cancer science, 113(2), 802-807 (2021-12-07)
Extramammary Paget's disease (EMPD) is a rare adnexal neoplasm commonly seen in the genital areas among the senior population. The prognosis of advanced EMPD is not favorable; thus, the development of potential treatments has long been sought. Cyclin-dependent kinase (CDK)
Abeer J Al-Qasem et al.
NPJ precision oncology, 6(1), 68-68 (2022-09-25)
Resistance to aromatase inhibitor (AI) treatment and combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) are crucial clinical challenges in treating estrogen receptor-positive (ER+) breast cancer. Understanding the resistance mechanisms and identifying reliable predictive biomarkers and novel treatment combinations to
Flora Doffe et al.
Cancers, 14(15) (2022-07-28)
The recent trend in 3D cell modeling has fostered the emergence of a wide range of models, addressing very distinct goals ranging from the fundamental exploration of cell-cell interactions to preclinical assays for personalized medicine. It is clear that no
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique